Amarin (NASDAQ:AMRN) Announces Earnings Results, Misses Expectations By $0.02 EPS

Amarin (NASDAQ:AMRN) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02), Zacks reports. The business had revenue of $42.30 million for the quarter, compared to analysts’ expectations of $43.82 million. Amarin had a negative return on equity of 7.15% and a negative net margin of 16.33%. During the same period in the prior year, the business posted ($0.05) earnings per share.

Amarin Price Performance

NASDAQ:AMRN traded up $0.01 during mid-day trading on Friday, hitting $0.59. The company’s stock had a trading volume of 803,613 shares, compared to its average volume of 1,547,164. The stock has a market cap of $240.73 million, a price-to-earnings ratio of -6.51 and a beta of 1.92. The business’s fifty day moving average is $0.60 and its two-hundred day moving average is $0.71. Amarin has a 1 year low of $0.56 and a 1 year high of $1.37.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.